Jentadueto

Jentadueto is a brand name of linagliptin/metformin, approved by the FDA in the following formulation(s):

JENTADUETO (linagliptin; metformin hydrochloride - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: January 30, 2012
  
  Strength(s): 2.5MG;1GM ^[RLD], 2.5MG;500MG, 2.5MG;850MG
  

Has a generic version of Jentadueto been approved?

No. There is currently no therapeutically equivalent version of Jentadueto available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jentadueto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Jentadueto.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 30, 2015 - NEW COMBINATION
  
  
  • May 2, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Jentadueto Consumer Information (Drugs.com)